-
Hey! Here is episode 05 of my
#lupus#webseries 2'20, and today we're talking about#interferons and#SLE, with a focus on#pDCs,#anifrolumab, and#JAK/STAT inhibitors in#Lupus. In less than 3 minutes, this is really a challenge. Please comment and let me know if you like it!!!pic.twitter.com/fTsQ48skx1 -
Take a look here, visual abstract
#anifrolumab
https://twitter.com/EricFMorand/status/1218041712389419009 …
-
The
#anifrolumab#TULIP2 phase 3 trial has successfully met its primary endpoint, as reported today by the promoter.
https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html …
This contrasts with the #TULIP1 trial which did not meet its primary endpoint as reported in August 2018.pic.twitter.com/nAePWvaN34
-
Now is the perfect timing
for a little spotlight
on #anifrolumab
and its recent development data in #Lupus
and it's #openaccess! https://www.dovepress.com/getfile.php?fileID=49740 …pic.twitter.com/7l37gWOHaw
-
#Anifrolumab#TULIP2,#belimumab#BLISSLN,#voclosporin#AURORA... and others that are coming. This is a great time (never thought) for#lupus treatment.https://twitter.com/NEJM/status/1207422788413227008 … -
TULIP 2 Successful phase 3 trial in
#lupus BICLA response 47.8% in#anifrolumab group vs 31.5% in placebo group (P=0.001) https://www.nejm.org/doi/full/10.1056/NEJMoa1912196 … -
This is good news for patients with
#SLE#anifrolumab met primary end point in TULIP2 so another step forward and another step closer to the clinic https://twitter.com/joraltron/status/1167136391555403782 … -

BIG PAPER ALERT
What a month for #lupus!!! The (positive) results of#anifrolumab#TULIP2 study are now published in the NEJM Link: https://www.nejm.org/doi/full/10.1056/NEJMoa191219 … Congrats to@EricFMorand@Lupusdoc@crichez33 and all other investigators & patients. -
Wonderful news for
#lupus. Can’t wait to read the paper -2020 could be a big year for lupus approvals with this plus#anifrolumab https://twitter.com/LupusOrg/status/1202341848817295360 … -
Visual summary
for #anifrolumab phase 3#RCTs in#Lupus#TULIP-1 and TULIP-2 Link to TULIP-1: https://doi.org/10.1016/S2665-9913(19)30076-1 … Link to TULIP-2: https://www.nejm.org/doi/full/10.1056/NEJMoa191219 …pic.twitter.com/VCaaNitTtW
-
You may have seen a Daily Mail article about the breakthrough
#lupus treatment#anifrolumab. We're excited about this potential treatment option, but felt the article was too sensationalist & didn't answer everyone's questions. Learn about this drug at https://www.lupusuk.org.uk/anifrolumab/ pic.twitter.com/8n34DGH8R0
-




New Drug




#Anifrolumab Anti interferon 1 receptor monoclonal antibody under trial for treatment of... http://fb.me/vlzMx3VC -
Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus. https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html …
#SLE#LES#lupus#anifrolumab#TULIP2@GEAS_SEMI@AutoinmunesP@GeasMadrid -
A bunch of failures in in
#SLE but some hope in#anifrolumab#ustekinumab#lupus#ACR19#RheumTwitter#MedTwitter#Rheumatology#Rheum#Arthritis#autoimmunepic.twitter.com/X6YjU7ndRq
-
Excellent talk on biologics in
#lupus by@edvital @ the NWL Lupus Forum!Highlighted the challenges of transitioning phase II>III RCT. Altho phase III for#Anifrolumab was overall -ve, it was +ve in INF-Hi http://subgroup.Gd example of immunologically stratified trial in#SLE -
Promising potential new treatment -
#anifrolumab https://twitter.com/LupusResearch/status/1167125535857815553 …
-
Really good results of TULIP 2 Trial
#anifrolumab in non-renal#SLE meeting primary#BICLA and secondary end-points#ACR19 . Wonderful news for#lupus community!!! -
#Anifrolumab shows positive results in#Lupus during Phase II clinical study http://ow.ly/V5Iii via@LupusOrg -
#SLE Trial success with#Anifrolumab hot off the press in@NEJM#lupus#rheumatology#autoimmune https://www.nejm.org/doi/full/10.1056/NEJMoa1912196?query=TOC … -
Patients with systemic
#lupus erythematosus had a higher rate of BICLA response with#anifrolumab compared with placebo, according to data from the TULIP-2 study via researchers@MonashUnihttps://www.healio.com/rheumatology/lupus/news/online/%7Be5a0c0f1-26cf-4382-b6ae-49fedee3843b%7D/tulip-2-anifrolumab-meets-bicla-endpoint-confers-higher-skin-response-rates-in-sle?utm_medium=social&utm_source=twitter&utm_campaign=scheduledpost …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.